CASI Pharmaceuticals, Inc. (CASI) financial statements (2020 and earlier)
Company profile
| Business Address |
9620 MEDICAL CENTER DR ROCKVILLE, MD 20850 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 54 | 85 | 43 | 27 | 5 | 11 | 15 | ||
| Cash and cash equivalents | 54 | 84 | 43 | 27 | 5 | 11 | 15 | ||
| Short-term investments | 1 | 1 | |||||||
| Receivables | 1 | 0 | (0) | ||||||
| Inventory, net of allowances, customer advances and progress billings | 5 | 0 | ✕ | ||||||
| Inventory | 5 | 0 | |||||||
| Other undisclosed current assets | 1 | 7 | 0 | 0 | 0 | 0 | 0 | ||
| Total current assets: | 62 | 93 | 44 | 27 | 6 | 11 | 15 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 9 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 1 | 2 | 1 | 0 | 0 | 0 | 0 | ||
| Long-term investments and receivables | 14 | ||||||||
| Long-term investments | 14 | ||||||||
| Intangible assets, net (including goodwill) | 17 | 19 | ✕ | ||||||
| Intangible assets, net (excluding goodwill) | 17 | 19 | |||||||
| Other noncurrent assets | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total noncurrent assets: | 41 | 21 | 1 | 0 | 0 | 0 | 0 | ||
| TOTAL ASSETS: | 103 | 113 | 45 | 28 | 6 | 11 | 16 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 8 | 2 | 3 | 1 | 1 | 1 | 1 | ||
| Accounts payable | 5 | 1 | 2 | 1 | 1 | 1 | 0 | ||
| Accrued liabilities | 3 | 1 | 1 | 0 | 0 | 0 | 0 | ||
| Debt | 1 | ||||||||
| Due to related parties | 2 | ||||||||
| Deferred revenue and credits | ✕ | ✕ | 0 | 0 | |||||
| Other undisclosed current liabilities | (0) | (0) | |||||||
| Total current liabilities: | 8 | 4 | 5 | 1 | 1 | 1 | 1 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1 | 1 | 1 | 1 | |||||
| Long-term debt, excluding current maturities | 1 | 1 | 1 | 1 | |||||
| Liabilities, other than long-term debt | 1 | 0 | 4 | 9 | 9 | ||||
| Other liabilities | 1 | 0 | |||||||
| Derivative instruments and hedges, liabilities | 4 | 9 | 9 | ||||||
| Total noncurrent liabilities: | 1 | 0 | 1 | 6 | 11 | 11 | |||
| Total liabilities: | 9 | 4 | 7 | 7 | 12 | 12 | 1 | ||
| Temporary equity, carrying amount | 21 | ||||||||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 73 | 109 | 39 | 21 | (6) | (0) | 15 | ||
| Common stock | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||
| Treasury stock, value | (8) | (8) | (8) | (8) | (8) | (8) | (8) | ||
| Additional paid in capital | 607 | 597 | 499 | 470 | 434 | 433 | 422 | ||
| Accumulated other comprehensive loss | (3) | (1) | |||||||
| Accumulated deficit | (524) | (479) | (453) | (442) | (432) | (425) | (399) | ||
| Warrants and rights outstanding | 9 | 8 | |||||||
| Other undisclosed stockholders' equity attributable to parent | (9) | (8) | |||||||
| Total stockholders' equity: | 73 | 109 | 39 | 21 | (6) | (0) | 15 | ||
| TOTAL LIABILITIES AND EQUITY: | 103 | 113 | 45 | 28 | 6 | 11 | 16 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 4 | 0 | 0 | |||||
| Revenue, net | ✕ | ✕ | 0 | 0 | ||||
| Cost of revenue | (9) | (0) | (0) | (20) | ||||
| Cost of goods and services sold | (4) | (0) | (0) | |||||
| Gross profit: | (4) | (0) | 0 | (20) | ||||
| Operating expenses | (43) | (27) | (11) | (9) | (7) | (7) | (6) | |
| Operating loss: | (47) | (27) | (11) | (9) | (7) | (26) | (6) | |
| Nonoperating income | 1 | |||||||
| Foreign currency transaction gain, before tax | 1 | |||||||
| Interest and debt expense | (0) | (0) | ||||||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 1 | (0) | 0 | |||||
| Loss from continuing operations before equity method investments, income taxes: | (45) | (27) | (11) | (9) | (7) | (26) | (6) | |
| Other undisclosed loss from continuing operations before income taxes | (0) | |||||||
| Net loss: | (45) | (27) | (11) | (9) | (7) | (26) | (6) | |
| Net income attributable to noncontrolling interest | 0 | |||||||
| Other undisclosed net income (loss) attributable to parent | (1) | (0) | (0) | 0 | ||||
| Net loss available to common stockholders, diluted: | (46) | (27) | (11) | (9) | (7) | (26) | (6) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (45) | (27) | (11) | (9) | (7) | (26) | (6) | |
| Other undisclosed comprehensive loss | (2) | |||||||
| Comprehensive loss: | (47) | (27) | (11) | (9) | (7) | (26) | (6) | |
| Comprehensive income, net of tax, attributable to noncontrolling interest | 0 | |||||||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (1) | |||||||
| Comprehensive loss, net of tax, attributable to parent: | (46) | (29) | (11) | (9) | (7) | (26) | (6) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.